首页|引火汤调节鞘氨醇-1-磷酸受体5信号通路对肺腺癌细胞增殖的影响

引火汤调节鞘氨醇-1-磷酸受体5信号通路对肺腺癌细胞增殖的影响

扫码查看
目的:探讨引火汤含药血清通过调控鞘氨醇-1-磷酸受体5/Kirsten鼠类肉瘤病毒癌基因/纤维肉瘤蛋白(S1PR5/KRAS/RAF)信号通路对肺腺癌细胞增殖的影响.方法:制备引火汤含药血清.应用不同浓度含药血清干预人非小细胞肺癌细胞(A549、H1299、PC9)24 h,确定最佳抑制浓度.使用最佳抑制浓度干预3种肺腺癌细胞24 h、48 h、72 h,确定最佳抑制时间及最敏感细胞株.采用慢病毒转染技术,构建稳定过表达S1PR5的肺腺癌细胞株,实验分为:OE NC组(空白血清+S1PR5过表达空载组)、OE S1PR5组(空白血清+S1PR5过表达组)、YHT+OE NC组(引火汤含药血清+S1PR5过表达空载组)、YHT+OE S1PR5组(引火汤含药血清+S1PR5过表达组).采用定量逆转录聚合酶链反应(qRT-PCR)和蛋白免疫印迹检测S1PR5/KRAS/RAF信号通路信使RNA(mRNA)及蛋白的表达情况.结果:采用细胞计数(CCK-8)结果显示在24 h时10%引火汤含药血清对A549、H1299、PC9细胞的抑制作用最显著(P<0.05,P<0.01),但10%引火汤含药血清干预时无明显的时间依赖性,因此选用10%引火汤含药血清作用24 h作为干预条件.因为引火汤含药血清对PC9细胞抑制率最高,因此选用PC9细胞进行机制验证.qRT-PCR结果表明S1PR5过表达组能够上调S1PR5 mRNA的表达水平(P<0.05);引火汤干预后能够降低S1PR5、KRAS、Ras相关的C3肉毒毒素底物1(RAC1)的表达(P<0.05).蛋白免疫印迹结果显示S1PR5过表达组S1PR5、KRAS、p-RAF1、丝裂原活化细胞外信号调节蛋白激酶1(p-MEK1)、磷脂酰肌醇3-激酶(p-PI3K)、RAC1蛋白表达显著升高(P<0.05);引火汤干预后,S1PR5、KRAS、p-RAF1、细胞外调节蛋白激酶1/2(p-ERK1/2)、RAC1蛋白表达显著降低(P<0.05).结论:引火汤含药血清能够通过下调S1PR5/KRAS/RAF信号通路抑制肺腺癌细胞增殖.
Effect of Yinhuotang on Lung Adenocarcinoma Cell Proliferation via Regulating Sphingosine-1-phosphate Receptor 5 Signaling Pathway
Objective:This study aimed to investigate the effect of Yinhuotang-containing serum on the proliferation of lung adeno-carcinoma cells via regulating the sphingosine-1-phosphate receptor 5/Kirsten rat sarcoma/rapid accelerated fibrosarcoma(S1 PR5/KRAS/RAF)signaling pathway.Methods:The Yinhuotang-containing serum was prepared.Different concentrations of drug-contai-ning serum were applied to intervene in human non-small lung cancer cells(A549,H1299,and PC9)for 24 h to determine the opti-mal inhibitory concentration.The optimal inhibitory concentration was used to intervene in three lung adenocarcinoma cells for 24 h,48 h,and 72 h,so as to determine the optimal inhibitory time and the most sensitive cell line.Lentiviral transfection was used to construct lung adenocarcinoma cell lines stably overexpressing S1PR5,and the experiments were divided into the following groups:OE NC group(blank serum+S1PR5 overexpression null group),OE S1PR5 group(blank serum+S1PR5 overexpression group),YHT+OE NC group(Yinhuotang-containing serum+S1PR5 overexpression null group),and YHT+OE S1PR5 group(Yinhuotang-containing serum+S1PR5 overexpression null group).Quantitative reverse transcription polymerase chain reaction(qRT-PCR)and Western blot(WB)methods were used to detect the expression of S1PR5/KRAS/RAF signaling pathway messen-ger RNA(mRNA)and proteins.Results:Cell counting kit-8(CCK-8)results showed that 10%Yinhuotang-containing serum had the most significant inhibitory effect on A549,H1299,and PC9 cells at 24 h(P<0.05,P<0.01),but there was no obvious time-dependence when 10%Yinhuotang-containing serum was used for intervention,so 24 h of action of 10%Yinhuotang-containing se-rum was chosen as the intervention condition.Because the highest inhibition rate of PC9 cells was observed in the Yinhuotang-con-taining serum,PC9 cells were selected for the mechanism verification.qRT-PCR results showed that the S1PR5 overexpression group was able to up-regulate the expression level of S1PR5 mRNA(P<0.05),and that Yinhuotang was able to reduce the expres-sion of S1PR5,KRAS,and Ras-related C3 botulinum toxin substrate 1(RAC1)(P<0.05).WB results showed that the protein ex-pression of S1PR5,KRAS,p-RAF1,mitogen-activated extracellular signal-regulated kinase1(p-MEK1),phosphatidylinositol-3-ki-nase(p-PI3K),and RAC1 in the S1PR5 overexpression group was significantly elevated(P<0.05).After the intervention of Yin-huotang,the protein expression of S1PR5,KRAS,p-RAF1,extracellular signal regulated kinase1/2(p-ERK1/2),and RAC1 was significantly reduced(P<0.05).Conclusion:Yinhuotang-containing serum inhibits the proliferation of lung adenocarcinoma cells through down-regulation of the S1PR5/KRAS/RAF signaling pathway.

Sphingosine-1-phosphate receptor 5Kirsten rat sarcomaRapid accelerated fibrosarcomaYinhuotangDrug-contai-ning serumLentiviral transfectionProliferationLung adenocarcinoma

王玥慧、李泉旺、林事成、梁天宇、庄垚雪、高磊、刘殿娜

展开 >

北京中医药大学,北京,100029

北京中医药大学东方医院肿瘤科,北京,100078

桐乡市中医医院重症医学科,嘉兴,314500

北京中医药大学东方医院科研处,北京,100078

展开 >

S1PR5 KRAS RAF 引火汤 含药血清 慢病毒转染 增殖 肺腺癌

2024

世界中医药
世界中医药学会联合会

世界中医药

CSTPCDCHSSCD北大核心
影响因子:1.266
ISSN:1673-7202
年,卷(期):2024.19(20)